MULTI-OBJECTIVE MODEL EXPLORATION OF HEPATITIS C ELIMINATION IN AN AGENT-BASED MODEL OF PEOPLE WHO INJECT DRUGS.


Journal

Proceedings of the ... Winter Simulation Conference. Winter Simulation Conference
ISSN: 0891-7736
Titre abrégé: Proc Winter Simul Conf
Pays: United States
ID NLM: 101614313

Informations de publication

Date de publication:
Dec 2019
Historique:
entrez: 7 7 2020
pubmed: 7 7 2020
medline: 7 7 2020
Statut: ppublish

Résumé

Hepatitis C (HCV) is a leading cause of chronic liver disease and mortality worldwide and persons who inject drugs (PWID) are at the highest risk for acquiring and transmitting HCV infection. We developed an agent-based model (ABM) to identify and optimize direct-acting antiviral (DAA) therapy scale-up and treatment strategies for achieving the World Health Organization (WHO) goals of HCV elimination by the year 2030. While DAA is highly efficacious, it is also expensive, and therefore intervention strategies should balance the goals of elimination and the cost of the intervention. Here we present and compare two methods for finding PWID treatment enrollment strategies by conducting a standard model parameter sweep and compare the results to an evolutionary multi-objective optimization algorithm. The evolutionary approach provides a pareto-optimal set of solutions that minimizes treatment costs and incidence rates.

Identifiants

pubmed: 32624641
doi: 10.1109/wsc40007.2019.9004747
pmc: PMC7335458
mid: NIHMS1604171
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1008-1019

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA043484
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121600
Pays : United States

Références

Lancet Infect Dis. 2018 Feb;18(2):215-224
pubmed: 29153265
Lancet Infect Dis. 2018 Feb;18(2):134-135
pubmed: 29153267
PLoS One. 2013 Jun 05;8(6):e64789
pubmed: 23755143
PLoS One. 2015 Sep 30;10(9):e0137993
pubmed: 26421722
Hepatology. 2014 Dec;60(6):1861-70
pubmed: 25163856
Hepatology. 2013 Nov;58(5):1523-5
pubmed: 23728921
World J Gastroenterol. 2007 May 7;13(17):2436-41
pubmed: 17552026
Hepatology. 2018 Mar;67(3):837-846
pubmed: 29059461
Proc Winter Simul Conf. 2016 Dec;2016:206-220
pubmed: 31239603
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432

Auteurs

Jonathan Ozik (J)

Decision and Infrastructure Sciences Division, Argonne National Laboratory, 5735 S Ellis Ave, Chicago, IL 60637, USA.

Harel Dahari (H)

Division of Hepatology, Dept of Medicine, Loyola University Medical Center, 2160 S 1st Ave, Maywood, IL 60153, USA.

Marian Major (M)

Division of Viral Products, US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA.

Basmattee Boodram (B)

School of Public Health, University of Illinois at Chicago, 1603 W Taylor St, Chicago, IL 60612, USA.

Classifications MeSH